Prostaglandin F2alpha antibody (HRP)

Catalog No. ABIN679697

Product Details anti-Prostaglandin F2alpha Antibody (HRP)

Target: Prostaglandin F2alpha

Reactivity: Hormone

Host: Rabbit

Clonality: Polyclonal

Conjugate: This Prostaglandin F2alpha antibody is conjugated to HRP

Application: ELISA, Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Cross-Reactivity: Rat

Cross-Reactivity (Details): PGF2 Alpha

Purification: Purified by Protein A.

Immunogen: KLH conjugated to PGF2 Alpha

Isotype: IgG

Application Details

Application Notes: IHC-P 1:100-500

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Preservative: Gentamicin sulfate

Precaution of Use: This product contains Gentamicin sulfate: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Do NOT add Sodium Azide! Use of Sodium Azide will inhibit enzyme activity of horseradish peroxidase.

Storage: -20 °C

Storage Comment: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Expiry Date: 12 months

Target Details for Prostaglandin F2alpha

Target: Prostaglandin F2alpha

Alternative Name: Pgf2 alpha (Prostaglandin F2alpha Products)

Target Type: Hormone

Background:

Synonyms: Prostaglandin F2 Alpha, PGF2 Alpha, 5Z,9,11,13E,15S-9,11,15-Trihydroxyprosta-5,13-dienoic acid tris salt, PGF2−,Tris.

Background: Luteolytic prostaglandin that induces parturition. Potent vasoconstrictor of pulmonary, coronary, and cerebral arteriole beds. A positive feedback loop between endometrial PG F2 and luteal oxytocin is responsible for completion of luteolysis.Luteolytic prostaglandin that induces parturition. Potent vasoconstrictor of pulmonary, coronary, and cerebral arteriole beds. Also stimulates contraction of smooth muscle, such as in bronchi, with possible involvement in asthma. This effect is at least partially mediated through tachykinin release.